Related Experiment Video
Updated: May 18, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
Pneumococcal vaccines for cystic fibrosis
Laura Burgess1, Kevin W Southern
1Alder Hey Children’s NHS Foundation Trust, Liverpool, UK. lauraburgess@nhs.net
No trials were found to assess pneumococcal vaccine efficacy in cystic fibrosis patients. Further epidemiological studies are needed to determine if pneumococcal immunization reduces morbidity and mortality in this population.
Area of Science:
- Medical research
- Immunology
- Pulmonology
Background:
- Invasive pneumococcal disease causes significant mortality.
- Pneumococcal vaccination is recommended for children and adults with cystic fibrosis in the USA and UK.
- Pneumococcal immunization may reduce pulmonary exacerbations in cystic fibrosis patients.
Purpose of the Study:
- To evaluate the effectiveness of pneumococcal vaccines in decreasing morbidity among individuals with cystic fibrosis.
Main Methods:
- Searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register.
- Contacted pharmaceutical manufacturers of pneumococcal vaccines.
- Included randomized and quasi-randomized controlled trials comparing pneumococcal vaccination to placebo or no vaccination.
Main Results:
- No relevant trials were identified for inclusion in this review.
Conclusions:
- No conclusions can be drawn regarding the efficacy of pneumococcal immunization in cystic fibrosis patients due to the absence of trials.
- Future randomized controlled trials are unlikely.
- Epidemiological studies may be valuable for assessing pneumococcal vaccination's impact on cystic fibrosis morbidity and mortality.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment